World Health Organisation (WHO) Evaluates Microdacyn for the Essential Medicines List

The World Health Organisation (WHO) Essential Medicines List (EML) committee considers Microdacyn technology during April 2017. Microdacyn is a super oxidised solution used to prevent and manage infection while clinically provides faster wound healing. The  Essential Medicines List contains carefully selected medicines and medical devices to meet the needs of near 84% of the worlds population, those living in poor, lower or middle income countries.


The EML is also a guide for the funded availability of medicines and medical devices through governments and organisations such as UNICEF.


A successful listing would mean the poor, lower and middle countries would be able to access the same wound care and infection control product Microdacyn, which is currently used in Australia, Europe, New Zealand and the USA.


The WHO is making a significant effort in sourcing non antibiotic technologies to combat the rising issue of drug resistance. WHO 2050 forecasts predict that drug resistance will be the leading case of death worldwide, greater than both cancer and cardiovascular disease.


Full details of the Microdacyn application are available to view here. Currently there is a substantial gap between countries in regard to wound care, for example the International Wound Infection Institute (IWII) 2016 guidelines note hydrogen peroxide products are not recommended, except in low income countries if no other products are available.


With the World Health Organisation (WHO) accepting a Microdacyn application lower income countries will be able to access the same products as the rest of world.


Background on the EML is here http://www.who.int/medicines/services/essmedicines_def/en/

For any queries please contact regulatory@tearaibiofarma.com

  • LinkedIn - Grey Circle
  • Facebook - Grey Circle
  • Instagram - Grey Circle

Te Arai BioFarma Ltd

Suite 2, Ground Floor

651 Doncaster Road

Doncaster  VIC  3108

©2017 Te Arai BioFarma Ltd | All rights reserved